Master's student takes top thesis competition while tackling prostate cancer research

December 17, 2010

The future of cancer treatment and a University of Alberta graduate student's personal career prospects are looking bright. Weiyang Liu beat competitors from 80 of the best university graduate schools in western North America with his master's thesis on the use of a light-sensitive drug to treat prostate cancer.

Liu, a U of A electrical engineering student, had his research reviewed internally at the U of A and was put forward as the university's sole entry into the annual master's thesis competition sponsored by the Western Association of Graduate Schools, which represents some 80 university graduate schools located in western Canada and the United States. He is part of the university's interdisciplinary team developing a two-technology treatment that specifically targets a cancerous .

Liu says the combination of drug treatment and the fibre-optics system could one day replace the long-standing treatments alternatives, chemotherapy or surgery. "Our prostate cancer drug is injected into a patient, but only begins killing cells when it's activated or turned on by , which is guided by tiny fibre-optic cables that have been inserted into the patient's prostate gland," said Liu. "This delivers the cancer treatment right to the prostate, unlike chemotherapy, which attacks the whole body."

And, unlike chemotherapy, Liu says the light-activated drug produces a natural cell death, which breaks down the in the prostate gland for normal absorption of dead cells by the patient's body. Statistics show that one in six Canadian men will require prostate cancer treatment. In his award-winning thesis, Liu also discussed the patient's fallout from surgical removal of the prostate. The surgical procedure can leave patients incontinent and impotent. "The high cost of surgery and the hospital stay can be avoided with photo-dynamic therapy," he says.

The drug component of the new treatment is already in clinical trials and the U of A team is hopeful that the fibre-optic light therapy will be added to human testing sometime next year. Liu and his supervising U of A professors, John Tulip and Ronald Moore, will travel to San Diego in March to receive the award. "I'm very proud that we won, when you consider the competition in western North America. We were up against large California schools like UCLA, CalTech and UC Berkeley," said Liu.

Related Stories

Recommended for you

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

US regulators approve 2nd gene therapy for blood cancer

October 19, 2017
U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet Dec 18, 2010
I find it kind of disconcerting a University would RATHER put forth a 'treatment' for prostate cancer but NOT put forth how prostate cancer is CAUSED by the stupidity of these SAME .. 'intelligent people'. They shouldn't be putting forth .. anything .. except an apology to the world .. FOR their stupidity. They are the ones' who FORCE the addition of the metal iron to all our foods. Therefore THEIR 'contribution' TO cancer research should be one of apologizing. Imho.
"Higher iron intake may be associated with risk of clinically aggressive prostate cancer"

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.